Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
CEREW was delisted on the 30th of August, 2021.
34 hedge funds and large institutions have $23.9M invested in Cerevel Therapeutics Holdings, Inc. Warrant in 2020 Q4 according to their latest regulatory filings, with 34 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.14M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.14M |
| 3 |
BlackRock
New York
|
+$956K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$945K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$941K |
Top Sellers
CEREW Hedge Fund Activity: Q4 2020 in Review
34 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Warrant (CEREW) for Q4 2020, worth a combined $23.9M.
Buyers outnumbered sellers: 34 funds opened new CEREW positions and 0 closed out — a net gain of 34 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Federated Hermes, opening a new position worth an estimated $1.14M.
- 34 institutional investors held Cerevel Therapeutics Holdings, Inc. Warrant (CEREW) as of Q4 2020, up from 0 in Q3 2020.
- Funds reported $23.9M of Cerevel Therapeutics Holdings, Inc. Warrant stock for Q4 2020.
- 34 funds opened new Cerevel Therapeutics Holdings, Inc. Warrant positions in Q4 2020 and 0 closed out, a net change of +34 holders.
- The largest Cerevel Therapeutics Holdings, Inc. Warrant buyer in Q4 2020 was Federated Hermes, an estimated $1.14M added.
Based on aggregated 13F filings for Q4 2020.